The combination therapy induced robust anti-tumor immunity by activating the cGAS–STING pathway, leading to increased infiltration of CD8+ T cells into the tumor microenvironment, significantly enhancing the observed therapeutic efficacy. This evidence concerns the gene CD8A and neoplasm.